Replimune Group Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Replimune Group Inc.
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Woburn
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
March
Ticker symbol
REPL
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001737953
EIN
82-2082553

Board of directors

Follow this board

Chief executives

Sushil Patel · Chief Executive Officer
Dates unknown
Philip Astley-Sparke · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of September 2, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

11 of this board's directors also sit on 29 other boards.

Network of Replimune Group Inc.'s board connections ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals... BeOne Medicines Ltd. BeOne Medicines Ltd. Bicycle Therapeutics plc Bicycle Therapeutics p... DBV Technologies S.A. DBV Technologies S.A. Denali Therapeutics Inc. Denali Therapeutics In... Immunocore Holdings plc Immunocore Holdings pl... Incyte Corp. Incyte Corp. Kiniksa Pharmaceuticals International plc Kiniksa Pharmaceutical... Kodiak Sciences Inc Kodiak Sciences Inc Kymera Therapeutics Inc. Kymera Therapeutics In... Madrigal Pharmaceuticals Inc. Madrigal Pharmaceutica... Neurogene Inc. Neurogene Inc. Prelude Therapeutics Incorporated Prelude Therapeutics I... TScan Therapeutics Inc. TScan Therapeutics Inc... vTv Therapeutics Inc. vTv Therapeutics Inc. Bicara Therapeutics Inc. Bicara Therapeutics In... Christy J. Oliger Christy J. Oliger Felix Baker Felix Baker Julian Baker Julian Baker Replimune Group Inc.
Shared director Other board Same sector +13 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$1,933,063
17 sales by 7 insiders
Date Insider Transaction Shares Price Value
Aug 20, 2026 Philip Astley-Sparke Director Gift −50,000 — —
Aug 17, 2026 Hill Emily Luisa Officer (Chief Financial Officer) Open-market sale −9,256 $14.28 $132,176
Aug 10, 2026 Hill Emily Luisa Officer (Chief Financial Officer) Open-market sale −11,448 $12.97 $148,481
Aug 10, 2026 Sushil Patel Director, Officer (Chief Executive Officer) Open-market sale −39,341 $12.97 $510,253
Aug 10, 2026 Schwendenman Andrew Officer (Chief Accounting Officer) Open-market sale −7,632 $12.97 $98,987
Aug 10, 2026 Xynos Konstantinos Officer (Chief Medical Officer) Open-market sale −11,447 $12.97 $148,468
Jun 1, 2026 Sarchi Christopher Officer (Chief Commercial Officer) Open-market sale −12,000 $9.24 $110,880
May 18, 2026 Xynos Konstantinos Officer (Chief Medical Officer) Open-market sale −14,023 $5.08 $71,237
May 18, 2026 Schwendenman Andrew Officer (Chief Accounting Officer) Open-market sale −7,894 $5.08 $40,102
May 18, 2026 Sarchi Christopher Officer (Chief Commercial Officer) Open-market sale −8,626 $5.08 $43,820
May 18, 2026 Philip Astley-Sparke Director Open-market sale −17,657 $5.08 $89,698
May 18, 2026 Sushil Patel Director, Officer (Chief Executive Officer) Open-market sale −37,324 $5.08 $189,606
May 18, 2026 Hill Emily Luisa Officer (Chief Financial Officer) Open-market sale −7,812 $5.08 $39,685
Apr 2, 2026 Sarchi Christopher Officer (Chief Commercial Officer) Open-market sale −6,500 $8.01 $52,065
Apr 1, 2026 Sarchi Christopher Officer (Chief Commercial Officer) Grant or award +50,000 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.